New ‘Diabetes type 5' discovered by scientists who say it's ‘vastly undiagnosed' – do you have the signs?
A NEW form of diabetes linked to malnutrition, not obesity, has been officially recognised.
Named Type 5 diabetes, the disease is estimated to affect 25million people worldwide.
It mainly strikes malnourished, lean teens and young adults in low and middle-income countries.
The International Diabetes Federation (IDF) voted to classify the condition previously known as Maturity Onset Diabetes of the Young (MODY) at its World Diabetes Congress in Bangkok on April 8th.
'It has historically been vastly underdiagnosed and poorly understood,' said Professor Meredith Hawkins of Albert Einstein College of Medicine, said.
'The IDF's recognition of it as 'Type 5 diabetes' is an important step toward raising awareness of a health problem that is so devastating to so many people," she added.
Globally, around 830 million adults are living with diabetes, mostly Type 1 and Type 2, according to a 2022 study.
Both types affect the body's ability to control blood sugar levels.
In Type 1 diabetes, the body can't produce insulin - a hormone that helps move sugar from the blood into cells for energy. This causes high blood sugar, which can damage organs.
In Type 2 diabetes, the body still makes insulin but becomes resistant to it, so sugar stays in the blood instead of entering the cells. Over time, this also leads to high blood sugar levels.
Type 5 diabetes is different. It's caused by malnutrition, which leads to low insulin production. The leaves the body unable to make enough insulin to manage blood sugar properly.
It's not due to a total lack of insulin like Type 1, or insulin resistance like Type 2 - rather the body doesn't produce enough, often because of poor nutrition.
40 Day Health Challenge GP Dr Sumi Dunne on signs and symptoms of diabetes to watch out for
Unlike Types 1 and 2, Type 5 is also usually inherited. If a parent carries the gene, their child has a 50 per cent chance of developing it, as the gene makes them more vulnerable to the condition.
Type 5 diabetes typically appears in early teens or 20s, especially in young men in Asia and Africa with a body mass index (BMI) of 19.
A healthy BMI is between 18 and 24.9, suggesting that those with Type 5 diabetes tend to be on the thinner side of healthy.
Professor Nihal Thomas, of Christian Medical College in India, told The Indian Express: 'The disease causes pancreatic beta cells to function abnormally, which leads to insufficient production of insulin.
"Due to the lack of formal recognition, this condition has been understudied and misdiagnosed.'
Doctors often mistake it for Type 1 diabetes - but giving insulin can be dangerous, Prof Hawkins told Medscape Medical News.
'Malnutrition-related diabetes is more common than tuberculosis and nearly as common as HIV/AIDS,' Prof Hawkins said.
'But the lack of an official name has hindered efforts to diagnose patients or find effective therapies.'
She first heard about the condition in 2005 when doctors from several countries described a strange form of diabetes.
"The patients were young and thin, which suggested that they had Type 1 diabetes, which can be managed with insulin injections to regulate blood sugar levels.
"But insulin didn't help these patients and in some cases caused dangerously low blood sugar," she said, according to Medical Express.
The patients did not seem to have Type 2 diabetes either, as it is typically associated with obesity, which the doctor said "was very confusing."
In 2010, Prof Hawkins founded Einstein's Global Diabetes Institute.
More than a decade later in 2022, Prof Hawkins and her colleagues at the Christian Medical College demonstrated that this form of diabetes was fundamentally different from Type 1 and 2.
She said people with Type 5 diabetes have a profound defect in the capacity to secrete insulin which wasn't recognised before.
This means their bodies can't properly absorb and store nutrients, especially sugar and fat to put on any weight, or store muscle.
As a result, they often stay very thin, even if they're eating enough.
'This finding has revolutionised how we think about this condition and how we should treat it," she said.
But there's still no standard treatment, with many patients dying within a year of diagnosis.
Prof Hawkins said diets high in protein and low in carbohydrates, along with targeted micronutrients, may help.
But she warned: 'This needs to be carefully studied now that there is global will and an official mandate from [IDF] to do so.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
16 hours ago
- Scottish Sun
We test portable health snacks ahead of festival season
One of these snacks is very moreish TRIED & TESTED We test portable health snacks ahead of festival season GLASTONBURY kicks off on Wednesday, meaning festival season is now in full swing. That's great if you like music, partying and booze, but not so brilliant if you are trying to keep on top of your health as food and drinks at venues come with high prices and low nutrients. Advertisement One of the best things you can do is take some healthy portable snacks. Today, I've put some to the test . . . Turkey bar 3 Roam free-range turkey bar is just 95 calories per 45g bar, with 16.7g of protein ROAM free-range turkey bar is just that – a meat bar with a 12-month shelf life that you don't need to put in the fridge. Perfect for festivals. Advertisement This is 91 per cent turkey meat, with some whey protein concentrate to boost the protein levels and some salt, sugar, flavourings, mustard, yeast extract and herbs. It is just 95 calories per 45g bar, with 16.7g of protein. This is a great idea – think of a Peperami type snack without all the additives and made with just natural ingredients. From £2 a bar. Advertisement 40 Day Health Challenge dietitian's top 10 tips for healthy snacking Seaweed crisps 3 Emily sriracha seaweed crisps look like a very thin prawn cracker with seaweed inside EMILY sriracha seaweed crisps are made out of just that – seaweed – which is a 'superfood' as it is rich in antioxidants, vitamins and minerals. It contains iodine, which is great for thyroid function. Advertisement Obviously, you're better off with fresh seaweed as these also contain tapioca, corn oil, rice powder, sugar, salt and dried molasses. They look like a very thin prawn cracker with seaweed inside. They're spicy, crunchy – but oddly soft at the same time. However, you get used to this. Advertisement These are moreish. They have a bit of an odd smell, but that would probably go unnoticed at a festival. These are 5 per cent fibre but 36 per cent fat and 98 calories for an 18g bag. They are on offer at Ocado for 80p. Advertisement Corn nibbles 3 Indulge crunchy corn nibbles were originally served as in-flight snacks Credit: Indulge INDULGE crunchy corn nibbles were originally served as in-flight snacks so they are packed with flavour because, when we're flying, the reduced moisture and lower air pressure diminish our sense of taste. I tried the Tex Mex cheese, which is made from corn, sunflower oil, salt, cheese flavouring, maltodextrin starch from potatoes, colouring from red pepper and an antioxidant. Advertisement These are five per cent fat and five per cent fibre. Only 99 calories per 20g bag. They are crunchy and cheesy, but there is a lot of powder on them, so wet wipes at the ready. The little bags are a bit fiddly too. Advertisement Don't try if you don't love corn, as you can certainly taste that, but a healthy on-the-go snack if you do. They are £7.99 for a multipack of eight at
Daily Mail
2 days ago
- Daily Mail
African gay men blame President Trump for their recent HIV diagnoses after he cut prevention funding
Gay men in Africa are blaming President Trump's decision to cut funding for HIV /AIDS prevention for their diagnoses of the virus. The administration's sweeping cuts to foreign aid have reduced access to medications like Pre-Exposure Prophylaxis, or PrEP, which decreases the risk of contracting HIV by 99 percent. Emmanuel Cherem, 25, a gay men in Nigeria, told Reuters that he tested positive for HIV two months after losing access to the US-supplied drug. 'I blame myself... Taking care of myself is my first duty as a person,' he said. 'I equally blame the Trump administration because, you know, these things were available, and then, without prior notice, these things were cut off.' Echezona, 30, another gay man from Nigeria, told Reuters that he took PrEP pills daily for three years until he was told by a clinic worker that the drug was now only available to pregnant and lactating women. 'I just pray and wish that Trump actually changes his policy and everything comes back to normal so that the spread and transmission of the virus would be reduced,' he said. Trump issued an executive order on his first day in office that paused foreign development assistance for 90 days, while Secretary of State Marco Rubio signed a 'stop work order' to employees of the State Department's Office of Foreign Assistance. The department oversees the US Agency for International Development (USAID) and the President's Emergency Plan for AIDS Relief (PEPFAR), which have seen drastic cuts since Trump took office. The administration has defended its position, arguing that other countries need to shoulder the burden of providing aid. During South African President Cyril Ramaphosa's White House visit, Trump acknowledged that the foreign aid cuts have been 'devastating.' 'Hopefully a lot of people are going to start spending a lot of money,' Trump added. 'I've talked to other nations. We want them to chip in and spend money too, and we've spent a lot,' he continued. 'And it's a big - it's a tremendous problem going on in many countries. A lot of problems going on. The United States always gets the request for money. Nobody else helps.' Russell Vought, the director of the US Office of Management and Budget, echoed Trump's stance during a Congressional committee meeting in early June. He argued that African countries should take on the responsibility of fighting HIV/AIDS, alleviating the financial burden on the US. Vought added that some of the nonprofits facilitating HIV prevention programs 'are not geared toward the viewpoints of the administration.' The director's comments are in line with a waiver issued to PEPFAR programs on February 1 allowing prevention programs to restart only for pregnant mothers. Vulnerable populations, like members of the LGBTQIA+ community, sex workers, or injecting drug users, weren't included in the prevention measures. PEPFAR grants often covered the cost of clinics supplying PrEP at public health centers for these populations, which have suffered closures due to decreased funding. A spokesperson for the State Department told Reuters that PEPFAR-funded programs would continue to be reviewed for 'assessment of programmatic efficiencies and consistency with United States foreign policy.' Public health officials and activists fear that if Trump's hardline policy toward foreign aid stays consistent, HIV infections will continue in the region. Linda-Gail Bekker, an HIV expert at the University of Cape Town, said that African countries may not cover the expense of supplying the drug, leaving a gap for more diagnoses. 'It's as predictable as if you take your eye off a smoldering bushfire and the wind is blowing: a bushfire will come back,' she told Reuters. Countries like Malawi, Zimbabwe, and Mozambique were almost entirely dependent on US funding for HIV prevention measures, according to UNAIDS. Other countries, like Ethiopia, responded to the USAID funding cuts by introducing a new payroll tax to pay for HIV medication previously provided by US funding. Medical advancements for HIV prevention and treatment have progressed significantly in recent years. However, UNAIDS projects that gaps created by a lack of funding could see steps backward.
The Independent
2 days ago
- The Independent
US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need
US medicines regulator the Food and Drug Administration (FDA) has approved a groundbreaking HIV prevention jab hailed as having the potential to quell the Aids pandemic. But the moment has been overshadowed by the spectre of aid cuts, placing in doubt whether this breakthrough injection – lenacapavir – will get to the people who need it most. Lenacapavir given in a twice-yearly injection stops HIV from replicating, protecting close to 100 per cent of people from developing the virus if they are exposed to it. This approval is one of the last crucial steps to getting the drug, branded Yeztugo, out to patients. Although the FDA's approval only applies to US patients, the World Health Organization (WHO) said it paved the way for its own recommendation of the drug and for approval in other countries. Director of WHO's Global HIV, Hepatitis and STI Programmes, Dr Meg Doherty described it as a 'regulatory milestone' adding: 'We are working with partners and national authorities to ensure lenacapavir reaches people who need it most – quickly, safely and equitably.' Researchers have raised concerns that, amid aid cuts, the jab will be too expensive to be taken up by lower-income countries. Gilead – the drugs company producing lencapavir – did not make public the cost of each dose to global funders but it announced a US price of $28,218 per year for each patient. 'If this game-changing medicine remains unaffordable, it will change nothing,' said Winnie Byanyima, executive director of the United Nations' Aids agency, UNAIDS. She called the approval of lenacapavir a 'breakthrough moment' adding the jab, 'could be the tool we need to bring new infections under control – but only if it is priced affordably and made available to everyone who could benefit. ' UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of roll out. It is beyond comprehension how Gilead can justify a price of $28,218.' Dr Andrew Hill, a pharmacology research fellow at the University of Liverpool, worked on the research which found lenacapavir could be provided for as little as $25, including a 30 per cent profit margin. 'Scientifically, it's a great moment that we have a drug which has been judged to be safe and efficacious by a leading regulatory authority in the world,'' he said. 'Public health-wise and in terms of the epidemic, it's tragic because the drug is so expensive that it's not going to get used'. It is also unlikely to be affordable in the UK, he said, despite government promises to end new cases of HIV in England by 2030. A Gilead spokesperson said, 'Yeztugo is priced in line with existing branded PrEP [pre-exposure prophylaxis] options. We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage in the US. 'We're taking unprecedented actions with urgency to plan for access to lenacapavir for PrEP globally—particularly in low- and lower-middle-income countries where the need is greatest.' Gilead signed agreements with six pharmaceutical companies in India, Pakistan, Egypt, and the US to allow them to make generic versions of the drug in order to increase supply and drive down the cost of the jab. This will take some time. Gilead also agreed to sell enough doses of the jab to protect at least two million people over three years in lower-income countries. These would be paid for by global funders led by the US President's Emergency Plan for Aids Relief (Pepfar) and the Global Fund to Fight Aids, Tuberculosis and Malaria. However, The Independent reported earlier in the month that these doses are now at risk because of US funding cuts. A significant chunk of the money to fund the doses of lenacapavir was set to come from the US-led global Aids response programme, Pepfar, as well as the Global Fund whose biggest donor was the US. This funding is now uncertain. Figures previously reported by The Independent suggest President Trump's slashing of foreign aid has derailed the projected end of the Aids pandemic and could lead to four million extra deaths by 2030. 'It does feel like this thing that could help us end the epidemic sooner is suddenly receding in the chaos,' said Prof Linda-Gail Bekker, whose trial demonstrated lenacapavir's effectiveness. The aid-funded doses are thought to cost much less than the US list price of almost $30k but still roughly five times more expensive than Dr Hill believes is necessary. And they are in an initial pilot phase, he said: 'We need to get into a different level where we're giving lenacapavir to tens of millions of people'. This is even more important as aid cuts are slashing the HIV prevention budgets of governments across Africa, he said. 'We're in this crazy position where we have a brand new highly effective vaccine-like drug and actually we will probably see the epidemic get worse over the next four years.'
